Related Experiment Video
Updated: Jul 14, 2026
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis
M G Neuman1, J P Benhamou, I M Malkiewicz
1Division of Clinical Pharmacology, E-240, Sunnybrook and Women's Health Sciences Centre, Department of Pharmacology, University of Toronto, 2075 Bayview Avenue, Toronto, M4N 3M5, Canada. manuela@sten.sunnybrook.utoronto.ca
Objectives:
(i) To characterize serum cytokine levels of tumor necrosis factor alpha (TNF alpha), interleukin 6 (IL 6), IL 8 and IL 12 in non-cirrhotic patients with chronic hepatitis C, (ii) to correlate the levels of these cytokines with the degree of the disease at the basal level, (iii) to correlate these levels with the response to therapy, (iv) to compare profiles of cytokines in monotherapy (MT) versus combination therapy (CT), and (v) to compare the immunomodulatory effects of MT versus CT.
Design And Methods:
47 patients were enrolled in the study. The controls were 120 volunteers (recruited from students and staff) that did not present HCV RNA positive and were not known to suffer any other metabolic disease. Thirty patients formed the other group of controls, with alcoholic liver disease (ALD). Serum cytokine levels were assessed using enzyme-linked immunosorbent assay (ELISA).
Results:
The sustained responders (SRs) have basal values much lower than relapsed responders (RRs) and non-responders (NRs) regardless of the therapy.
Conclusions:
Cytokines can be used as non-invasive markers for sustained response and as monitors for the outcome of therapy.
More Related Videos
Related Concept Videos
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test